These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

556 related items for PubMed ID: 33799055

  • 1. Mobile app-based chatbot to deliver cognitive behavioral therapy and psychoeducation for adults with attention deficit: A development and feasibility/usability study.
    Jang S, Kim JJ, Kim SJ, Hong J, Kim S, Kim E.
    Int J Med Inform; 2021 Jun; 150():104440. PubMed ID: 33799055
    [Abstract] [Full Text] [Related]

  • 2. Mental Health Chatbot for Young Adults With Depressive Symptoms During the COVID-19 Pandemic: Single-Blind, Three-Arm Randomized Controlled Trial.
    He Y, Yang L, Zhu X, Wu B, Zhang S, Qian C, Tian T.
    J Med Internet Res; 2022 Nov 21; 24(11):e40719. PubMed ID: 36355633
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy of mobile app-based interactive cognitive behavioral therapy using a chatbot for panic disorder.
    Oh J, Jang S, Kim H, Kim JJ.
    Int J Med Inform; 2020 Aug 21; 140():104171. PubMed ID: 32446158
    [Abstract] [Full Text] [Related]

  • 5. Chatbot-Delivered Cognitive Behavioral Therapy in Adolescents With Depression and Anxiety During the COVID-19 Pandemic: Feasibility and Acceptability Study.
    Nicol G, Wang R, Graham S, Dodd S, Garbutt J.
    JMIR Form Res; 2022 Nov 22; 6(11):e40242. PubMed ID: 36413390
    [Abstract] [Full Text] [Related]

  • 6. Feasibility, Acceptability, and Preliminary Efficacy of a Smartphone App-Led Cognitive Behavioral Therapy for Depression Under Therapist Supervision: Open Trial.
    Wilhelm S, Bernstein EE, Bentley KH, Snorrason I, Hoeppner SS, Klare D, Greenberg JL, Weingarden H, McCoy TH, Harrison O.
    JMIR Ment Health; 2024 Apr 09; 11():e53998. PubMed ID: 38592771
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of a Web-based and Mobile Therapy Chatbot on Anxiety and Depressive Symptoms in Subclinical Young Adults: Randomized Controlled Trial.
    Karkosz S, Szymański R, Sanna K, Michałowski J.
    JMIR Form Res; 2024 Mar 20; 8():e47960. PubMed ID: 38506892
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Feasibility and impact of a mental health chatbot on postpartum mental health: a randomized controlled trial.
    Suharwardy S, Ramachandran M, Leonard SA, Gunaseelan A, Lyell DJ, Darcy A, Robinson A, Judy A.
    AJOG Glob Rep; 2023 Aug 20; 3(3):100165. PubMed ID: 37560011
    [Abstract] [Full Text] [Related]

  • 11. User-Friendly Chatbot to Mitigate the Psychological Stress of Older Adults During the COVID-19 Pandemic: Development and Usability Study.
    Chou YH, Lin C, Lee SH, Lee YF, Cheng LC.
    JMIR Form Res; 2024 Mar 13; 8():e49462. PubMed ID: 38477965
    [Abstract] [Full Text] [Related]

  • 12. Using AI chatbots to provide self-help depression interventions for university students: A randomized trial of effectiveness.
    Liu H, Peng H, Song X, Xu C, Zhang M.
    Internet Interv; 2022 Mar 13; 27():100495. PubMed ID: 35059305
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of Zemedy, a Mobile Digital Therapeutic for the Self-management of Irritable Bowel Syndrome: Crossover Randomized Controlled Trial.
    Hunt M, Miguez S, Dukas B, Onwude O, White S.
    JMIR Mhealth Uhealth; 2021 May 20; 9(5):e26152. PubMed ID: 33872182
    [Abstract] [Full Text] [Related]

  • 14. Neurofeedback, sham neurofeedback, and cognitive-behavioural group therapy in adults with attention-deficit hyperactivity disorder: a triple-blind, randomised, controlled trial.
    Schönenberg M, Wiedemann E, Schneidt A, Scheeff J, Logemann A, Keune PM, Hautzinger M.
    Lancet Psychiatry; 2017 Sep 20; 4(9):673-684. PubMed ID: 28803030
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cannabis Use in Adults Who Screen Positive for Attention Deficit/Hyperactivity Disorder: CANreduce 2.0 Randomized Controlled Trial Subgroup Analysis.
    Ahlers J, Baumgartner C, Augsburger M, Wenger A, Malischnig D, Boumparis N, Berger T, Stark L, Ebert DD, Haug S, Schaub MP.
    J Med Internet Res; 2022 Apr 20; 24(4):e30138. PubMed ID: 35442196
    [Abstract] [Full Text] [Related]

  • 17. Cognitive behavioural group therapy as addition to psychoeducation and pharmacological treatment for adolescents with ADHD symptoms and related impairments: a randomised controlled trial.
    Haugan AJ, Sund AM, Young S, Thomsen PH, Lydersen S, Nøvik TS.
    BMC Psychiatry; 2022 Jun 02; 22(1):375. PubMed ID: 35655149
    [Abstract] [Full Text] [Related]

  • 18. Feasibility, Usability, and Effectiveness of a Machine Learning-Based Physical Activity Chatbot: Quasi-Experimental Study.
    To QG, Green C, Vandelanotte C.
    JMIR Mhealth Uhealth; 2021 Nov 26; 9(11):e28577. PubMed ID: 34842552
    [Abstract] [Full Text] [Related]

  • 19. Use of the Chatbot "Vivibot" to Deliver Positive Psychology Skills and Promote Well-Being Among Young People After Cancer Treatment: Randomized Controlled Feasibility Trial.
    Greer S, Ramo D, Chang YJ, Fu M, Moskowitz J, Haritatos J.
    JMIR Mhealth Uhealth; 2019 Oct 31; 7(10):e15018. PubMed ID: 31674920
    [Abstract] [Full Text] [Related]

  • 20. A Therapeutic Relational Agent for Reducing Problematic Substance Use (Woebot): Development and Usability Study.
    Prochaska JJ, Vogel EA, Chieng A, Kendra M, Baiocchi M, Pajarito S, Robinson A.
    J Med Internet Res; 2021 Mar 23; 23(3):e24850. PubMed ID: 33755028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.